2023 annual financial data
Foghorn Therapeutics 2023 Operating cash flow margin
Direct answer
Operating cash flow margin was -345.79%.
Operating income was -107,906,000 USD and net income was -98,426,000 USD.
Operating cash flow was -118,106,000 USD.
Get free Foghorn Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 34,155,000 USD
- Operating income
- -107,906,000 USD
- Net income
- -98,426,000 USD
- Operating cash flow
- -118,106,000 USD